MacroGenics, Inc. (NASDAQ:MGNX) Shares Acquired by Fmr LLC

Fmr LLC increased its position in MacroGenics, Inc. (NASDAQ:MGNXFree Report) by 1,230.1% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 137,215 shares of the biopharmaceutical company’s stock after purchasing an additional 126,899 shares during the period. Fmr LLC owned 0.22% of MacroGenics worth $451,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its position in MacroGenics by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,064 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 4,707 shares during the period. DRW Securities LLC purchased a new position in shares of MacroGenics during the second quarter worth approximately $56,000. K2 Principal Fund L.P. acquired a new position in shares of MacroGenics in the 2nd quarter valued at $63,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in MacroGenics by 300.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,072 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 12,060 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in MacroGenics during the 3rd quarter worth $55,000. 96.89% of the stock is owned by institutional investors and hedge funds.

MacroGenics Trading Down 0.9 %

Shares of MGNX stock opened at $3.18 on Friday. The stock has a 50 day simple moving average of $3.66 and a 200-day simple moving average of $3.87. The company has a market cap of $199.59 million, a price-to-earnings ratio of -2.01 and a beta of 2.04. MacroGenics, Inc. has a 12-month low of $2.95 and a 12-month high of $21.88.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Evercore ISI upgraded shares of MacroGenics to a “strong-buy” rating in a research note on Monday, September 16th. JMP Securities cut MacroGenics from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 7th. HC Wainwright reaffirmed a “neutral” rating and set a $4.00 price objective on shares of MacroGenics in a research note on Wednesday, November 6th. Finally, StockNews.com upgraded MacroGenics from a “sell” rating to a “buy” rating in a research note on Sunday, November 10th. Eight analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $7.63.

Check Out Our Latest Analysis on MGNX

About MacroGenics

(Free Report)

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.

Featured Stories

Want to see what other hedge funds are holding MGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MacroGenics, Inc. (NASDAQ:MGNXFree Report).

Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.